DownRightNowNews
Trending
EdenTree fund manager Hiorns has bought up French stocks despite civil unrestHuge setback for Alberta's separatist movement after decisive defeatIndonesia’s experiment with populism is waveringSwimmer, 65, killed in shark attack off South Africa's east coastSudan army drones hit mourners and fuel market killing more than 200 people, sources saySuper Bagyong Rosal updates | SONADepEd orders schools to brace for disruptions as Rosal approachesSara Duterte accuses Marcos gov’t of using China, Laos issues to bring her downEdenTree fund manager Hiorns has bought up French stocks despite civil unrestHuge setback for Alberta's separatist movement after decisive defeatIndonesia’s experiment with populism is waveringSwimmer, 65, killed in shark attack off South Africa's east coastSudan army drones hit mourners and fuel market killing more than 200 people, sources saySuper Bagyong Rosal updates | SONADepEd orders schools to brace for disruptions as Rosal approachesSara Duterte accuses Marcos gov’t of using China, Laos issues to bring her down
Technology

AI startup ASI valued at $3 billion in latest funding round

·1h ago
Share:PostShare

Oct 20 : Artificial intelligence startup ASI said on Tuesday it had raised $325 million in a funding round valuing the company at $3 billion, amid growing investor appetite for AI software used in real-world applications. Here are more details:• The Series C round was led by Spark Capital, with partic

C

Channel Newsasia

Original source

Read full story
BusinessBanking & Finance

Related Stories

Technology7h ago

NeuroXT Inc. Receives U.S. FDA 510(k) Clearance for NEXT-Cue, AI Software Supporting Prognostic Assessment in Mild Cognitive Impairment

Supports clinicians in assessing progression from mild cognitive impairment to Alzheimer's dementia within five years NeuroXT Inc. to advance U.S. commercialization and adoption by healthcare institutions following FDA 510(k) clearance SEOUL, South Korea, Oct. 20, 2026 /PRNewswire/ -- NeuroXT Inc., a medical device manufacturer, announced that NEXT-Cue, its AI-based Software as a Medical Device (SaMD) supporting prognostic assessment in patients with mild cognitive impairment (MCI), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) as a Class II medical device. NEXT-Cue supports clinicians in assessing patients with MCI who are being evaluated for progression to Alzheimer's dementia within five years. By integrating brain MRI images, demographic information, and cognitive assessment data, it provides supplementary information to support clinical assessment and individualized patient management planning. "Receiving FDA 510(k) clearance marks an important milestone in NeuroXT's entry into the U.S. healthcare market," said Joon-Kyung Seong, CEO of NeuroXT Inc. "Starting with NEXT-Cue, we plan to establish real-world clinical use cases at leading healthcare institutions across the United States and accelerate our commercialization efforts, with the broader goal of contributing to earlier diagnosis and appropriate treatment of Alzheimer's disease." NeuroXT Inc. is also pursuing regulatory authorization for NEXT-Cue from the Ministry of Food and Drug Safety (MFDS) in the Republic of Korea and plans to begin commercialization in the Korean market early next year. About NeuroXT Inc. NeuroXT Inc. is a medical AI company specializing in the development of AI-based imaging biomarkers for Alzheimer's disease. The company is developing AI technologies that primarily use MRI imaging to assess Alzheimer's disease-related pathology and potential treatment response. Through precision medicine solutions designed to help identify optimal treatment timing for individual patients, NeuroXT Inc. aims to advance the treatment of Alzheimer's disease.

PPr Newswire Apac

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer